Filing Analysis
Nuvectis Pharma, Inc. has entered into a new 'At the Market' (ATM) offering agreement with Jefferies LLC to sell common stock. This follows the termination of a previous ATM program and is supported by a new $200 million shelf registration statement.
🚩 Red Flags
- Potential for significant shareholder dilution through the $200 million ATM program.
- The termination of a previous ATM program suggests a need for fresh capital or a restructuring of financing needs.
📋 Key Facts
- Entered into an Open Market Sale Agreement with Jefferies LLC on August 21, 2026.
- The company filed a new S-3 shelf registration statement on August 21, 2026, to register $200 million in securities.
- Jefferies LLC will act as the sales agent for the ATM shares.
- Jefferies will receive compensation of up to 3.0% of the gross proceeds.
- The company terminated its prior ATM program (established Feb 13, 2026) on July 20, 2026.
Nuvectis Pharma, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2026. The filing serves as a vehicle to furnish a corporate update and press release regarding recent operations.
📋 Key Facts
- Report date: August 4, 2026
- Reporting period: Second quarter ended June 30, 2026
- The filing includes an earnings press release as Exhibit 99.1
- Company is classified as an 'emerging growth company'
Nuvectis Pharma, Inc. entered into an underwriting agreement with Cantor Fitzgerald & Co. to conduct a firm commitment public offering of 5,000,000 common shares at $20.00 per share. The offering is expected to generate approximately $93 million in net proceeds and is scheduled to close on July 1, 2026.
🚩 Red Flags
- Significant dilution for existing shareholders due to the issuance of 5 million new shares.
📋 Key Facts
- Underwriter: Cantor Fitzgerald & Co.
- Offering size: 5,000,000 firm shares plus an option for an additional 750,000 shares.
- Price per share: $20.00.
- Expected net proceeds: ~$93 million (up to ~$107 million if over-allotted).
- Closing date: Expected July 1, 2026.
- Registration basis: Effective shelf registration statement on Form S-3.
Nuvectis Pharma has suspended its existing at-the-market (ATM) sales agreement with Leerink Partners LLC. The company is also reducing the total aggregate amount available for future sales under this agreement to $5 million.
🚩 Red Flags
- Suspension of equity sales often indicates a lack of market appetite for the company's stock at current price levels.
- Reduction in available capital (lowering the cap to $5M) suggests limited liquidity runway or strategic shift in financing needs.
📋 Key Facts
- On June 29, 2026, the Company suspended its Sales Agreement Prospectus with Agent Leerink Partners LLC.
- The Company determined to lower the maximum amount available for sales under the Sales Agreement to $5 million.
- No further shares will be sold under this specific agreement until a new prospectus or registration statement is filed.
- The underlying Sales Agreement remains in full force and effect.
Nuvectis Pharma entered into a significant license agreement with Haisco Pharmaceutical Group Co., Ltd. to acquire exclusive rights for the development and commercialization of two late-stage assets: NXP100 (a Complement Factor B inhibitor) and NXP200 (a BRAF inhibitor). The deal involves substantial contingent liabilities including up to $1.4 billion in milestone payments.
🚩 Red Flags
- Significant contingent liabilities: Up to $1.4 billion in potential milestone payments could severely impact future cash flows.
- Financing contingency: The agreement is subject to the company meeting financing conditions, indicating current capital constraints or uncertainty regarding funding for these assets.
📋 Key Facts
- Entered into License Agreement with Haisco Pharmaceutical Group Co., Ltd. on June 22, 2026.
- Acquired rights for NXP100 (Complement Factor B inhibitor) and NXP200 (BRAF inhibitor).
- Upfront payment of $20 million required.
- Initial development milestone payments up to $20 million.
- Contingent milestone payments totaling up to $1.4 billion based on regulatory/commercial success.
- Tiered royalties in the high-single digits to mid-teens based on net sales.
- Agreement is subject to financing conditions to ensure sufficient capital for development.
- Includes a change of control provision requiring payment of low double-digit % of fair market value if acquired within 18 months.
Nuvectis Pharma reported the results of its 2026 Annual Meeting held on June 11, 2026. All proposals, including the election of a Class I director and the ratification of the independent auditor, were approved.
🚩 Red Flags
- Inadvertent misstatement of total shares outstanding in the Definitive Proxy Statement filed on April 27, 2026.
📋 Key Facts
- Annual Meeting held on June 11, 2026, with a quorum of 60.8% (16,193,686 shares) present.
- Proposal 1: Ron Bentsur was elected as Class I director (8,354,838 votes For).
- Proposal 2: Kesselman & Kesselman was ratified as the independent registered public accounting firm for fiscal year ending December 31, 2026 (15,662,222 votes For).
- The company corrected a previous misstatement in the Proxy Statement regarding shares outstanding: the correct number as of April 13, 2026, was 26,614,628, not 27,668,036.
Nuvectis Pharma, Inc. announced its financial results for the first quarter ended March 31, 2026, and provided a corporate update. The information was furnished via a press release on May 5, 2026.
📋 Key Facts
- The filing reports financial results for the first quarter ended March 31, 2026
- The report was filed under Item 2.02 (Results of Operations and Financial Condition)
- A press release containing the corporate update and financial results was furnished as Exhibit 99.1
- The report was signed by Chairman, CEO, and President Ron Bentsur
Nuvectis Pharma, Inc. filed an 8-K to furnish a press release containing its corporate update and financial results for the fiscal year ended December 31, 2025.
📋 Key Facts
- Report date: February 11, 2026
- Reporting period: Fiscal year ended December 31, 2025
- The filing includes a press release (Exhibit 99.1) providing financial results and a corporate update.
- Company is classified as an 'emerging growth company'.
Nuvectis Pharma, Inc. filed an 8-K to announce the release of its third quarter financial results for the period ended September 30, 2025.
🚩 Red Flags
- None identified in the provided text; however, full risk assessment requires reviewing the actual financial results in Exhibit 99.1 (not provided).
📋 Key Facts
- Report date: November 4, 2025
- Reporting period: Third Quarter ended September 30, 2025
- The filing is a corporate update and financial results announcement (Item 2.02).
- Information in Exhibit 99.1 is furnished but not 'filed' for purposes of Section 18 liability.
Nuvectis Pharma, Inc. announced the appointment of Juan Sanchez, MD, to its Board of Directors on September 22, 2025.
📋 Key Facts
- Juan Sanchez, MD, was appointed to the Board of Directors on September 22, 2025.
- Dr. Sanchez will serve until his term expires at the 2026 annual meeting of stockholders.
- The appointment was announced via press release on September 25, 2025.
Nuvectis Pharma, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2025. The filing serves as a vehicle to furnish a corporate update and related press release.
📋 Key Facts
- Report date: August 5, 2025
- Reporting Period: Second Quarter ended June 30, 2025
- The filing includes Exhibit 99.1, which contains the corporate update and financial results.
- Company is classified as an 'emerging growth company'.
Nuvectis Pharma, Inc. held its 2025 Annual Meeting of Stockholders on June 12, 2025, where all proposed items were approved by stockholders.
📋 Key Facts
- The 2025 Annual Meeting was held via an online meeting platform on June 12, 2025.
- Quorum was established with 14,605,167 shares (61.86%) of the 23,606,443 total outstanding shares present or represented by proxy.
- Proposal 1: James Oliviero was elected to the Class III director seat until the 2028 annual meeting with 9,882,555 votes in favor.
- Proposal 2: Kesselman & Kesselman was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2025, with 14,561,983 votes in favor.
Nuvectis Pharma, Inc. has entered into a new $60 million 'At the Market' (ATM) offering agreement with Leerink Partners LLC to sell common stock. This replaces a previously terminated $40 million ATM program with H.C. Wainwright & Co.
🚩 Red Flags
- Potential for significant shareholder dilution through continuous issuance of common stock via the ATM program.
📋 Key Facts
- Entered into Sales Agreement with Leerink Partners LLC on May 9, 2025.
- New ATM offering capacity is up to $60 million in common stock.
- Leerink Partners will receive a 3.0% commission on gross proceeds.
- Terminated previous $40 million ATM program with H.C. Wainwright & Co., LLC.
- Approximately $18.6 million was previously sold under the terminated HCW ATM.
Nuvectis Pharma, Inc. filed an 8-K to announce its corporate update and financial results for the first quarter ended March 31, 2025.
📋 Key Facts
- Report date: May 6, 2025
- Reporting period: First Quarter ended March 31, 2025
- The filing includes a press release (Exhibit 99.1) providing corporate and financial updates.
- Company is classified as an 'emerging growth company'.
Nuvectis Pharma, Inc. filed an 8-K to furnish a press release containing a corporate update and financial results for the fiscal year ended December 31, 2024.
📋 Key Facts
- Report date: February 25, 2025
- The filing pertains to results of operations and financial condition (Item 2.02).
- Covers the fiscal year ended December 31, 2024.
- Includes a corporate update via Exhibit 99.1.
Nuvectis Pharma, Inc. entered into a firm commitment underwriting agreement with Lucid Capital Markets, LLC to conduct a public offering of common stock. The offering consists of 2,700,000 shares at $5.00 per share, plus an option for the underwriter to purchase an additional 405,000 shares which has already been fully exercised.
🚩 Red Flags
- Dilutive event: Issuance of up to 3,105,000 new shares will dilute existing shareholders.
📋 Key Facts
- Underwriting agreement signed on February 5, 2025, with Lucid Capital Markets, LLC.
- Total firm shares: 2,700,000 common stock at $5.00 per share.
- Over-allotment option of 405,000 shares was fully exercised by the underwriter.
- Expected net proceeds to the company are approximately $14.4 million after commissions.
- The offering is being conducted via an effective shelf registration statement on Form S-3 (File No. 333-270657).
- Closing of the transaction is expected on February 6, 2025.
Nuvectis Pharma, Inc. filed an 8-K to announce its third quarter financial results for the period ended September 30, 2024. The filing serves as a vehicle to furnish a corporate update and press release via Exhibit 99.1.
📋 Key Facts
- Report date: November 5, 2024
- Reporting period: Third quarter ended September 30, 2024
- The filing includes a press release (Exhibit 99.1) providing a corporate update and financial results.
- Company is classified as an 'emerging growth company'.
Nuvectis Pharma, Inc. announced that it has received Orphan Drug Designation from the FDA for its drug candidate NXP800 in the treatment of Ovarian Cancer.
📋 Key Facts
- FDA granted Orphan Drug Designation for NXP800 for Ovarian Cancer on August 29, 2024.
- The announcement was made via a press release furnished as Exhibit 99.1.
- Company is classified as an emerging growth company.
Nuvectis Pharma, Inc. filed an 8-K to announce its second quarter financial results for the period ended June 30, 2024. The filing serves as a vehicle to furnish a corporate update and related press release.
📋 Key Facts
- Report date: August 6, 2024
- Reporting period: Second quarter ended June 30, 2024
- The company is an 'emerging growth company' as defined by the SEC.
- The filing includes a press release (Exhibit 99.1) containing corporate updates and financial results.
Nuvectis Pharma, Inc. held its 2024 Annual Meeting of Stockholders on June 13, 2024. All proposals presented at the meeting were approved by shareholders.
📋 Key Facts
- The 2024 Annual Meeting was held via an online meeting platform on June 13, 2024.
- Quorum was established with 12,227,134 shares (66.55%) of the 18,370,758 shares outstanding present in person or by proxy.
- Proposal 1: Election of Class II directors Kenneth Hoberman and Matthew Kaplan to hold office until the 2027 annual meeting was approved.
- Proposal 2: Ratification of Kesselman & Kesselman as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 was approved with 12,055,252 votes in favor.
Nuvectis Pharma, Inc. filed an 8-K to announce its first quarter financial results for the period ended March 31, 2024 via a press release.
📋 Key Facts
- Report date: May 7, 2024
- Reporting Period: Q1 ended March 31, 2024
- The filing is for Item 2.02 (Results of Operations and Financial Condition)
- Company is classified as an emerging growth company
Nuvectis Pharma, Inc. filed an 8-K to furnish a press release containing a corporate update and financial results for the fiscal year ended December 31, 2023.
📋 Key Facts
- Report date: March 5, 2024
- Reporting period: Fiscal year ended December 31, 2023
- The filing includes a press release (Exhibit 99.1) regarding financial results and corporate updates.
- Company is an emerging growth company.